PALFYDE Trademark

Trademark Overview

On Thursday, May 4, 2023, a trademark application was filed for PALFYDE with the United States Patent and Trademark Office. The USPTO has given the PALFYDE trademark a serial number of 97920353. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, December 5, 2024. This trademark is owned by Crinetics Pharmaceuticals, Inc.. The PALFYDE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use
palfyde

General Information

Serial Number97920353
Word MarkPALFYDE
Filing DateThursday, May 4, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, December 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine-related diseases; pharmaceutical preparations for the treatment of acromegaly, carcinoid syndrome, neuroendocrine tumors, and cancer; all for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 9, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCrinetics Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameCrinetics Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Monday, May 8, 2023NEW APPLICATION ENTERED
Tuesday, January 30, 2024ASSIGNED TO EXAMINER
Tuesday, January 30, 2024NON-FINAL ACTION E-MAILED
Tuesday, May 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 30, 2024NON-FINAL ACTION WRITTEN
Tuesday, January 30, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 28, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, February 28, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, February 28, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 6, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 6, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 30, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, April 5, 2024FINAL REFUSAL WRITTEN
Friday, April 5, 2024FINAL REFUSAL E-MAILED
Friday, April 5, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, May 31, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 19, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 3, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, December 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 9, 2024PUBLISHED FOR OPPOSITION
Thursday, December 5, 2024SOU EXTENSION 1 FILED
Friday, December 6, 2024SOU EXTENSION 1 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

palfyde preparations pharmaceutical endocrine human syndrome neuroendocrine tumors carcinoid cancer diseases